Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy

INTRODUCTION: Narsoplimab is a human monoclonal antibody against mannan-associated lectin-binding serine protease−2 (MASP-2). Now in a phase 3 study, narsoplimab was evaluated in a staged phase 2 study assessing safety and effectiveness in high-risk patients with IgA nephropathy (IgAN). METHODS: Sub...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Kidney Int Rep
Glavni autori: Lafayette, Richard A., Rovin, Brad H., Reich, Heather N., Tumlin, James A., Floege, Jürgen, Barratt, Jonathan
Format: Artigo
Jezik:Inglês
Izdano: Elsevier 2020
Teme:
Clinical Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7609886/
https://ncbi.nlm.nih.gov/pubmed/33163724
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ekir.2020.08.003
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items